Focus:
News
-
15 October 2019
Sanofi opens digital manufacturing facility in the US
French pharmaceutical giant Sanofi has opened a digital manufacturing facility at Framingham in Massachusetts, the US for continuous production of biologics.
-
15 October 2019
Xarelto gets approval to prevent blood clots in acutely ill patients
Janssen Pharmaceutical has received the US Food and Drug Administration (FDA) approval for Xarelto (rivaroxaban) to prevent venous thromboembolism (VTE) or blood clots.
-
14 October 2019
Pfizer’s JAK1 inhibitor performs well in atopic dermatitis
Pfizer has announced promising results from its Phase III JADE MONO-1 study of janus kinase 1 (JAK1) inhibitor abrocitinib in atopic dermatitis.
-
14 October 2019
Lilly receives FDA approval for migraine drug Reyvow
Eli Lilly has obtained the US Food and Drug Administration (FDA) approval for Reyvow in the acute treatment of adults suffering from migraine, with or without aura.
-
14 October 2019
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB).
-
14 October 2019
NICE approves Clovis Oncology’s rucaparib for CDF use
The National Institute for Health and Care Excellence (NICE), UK has approved Clovis Oncology’s ovarian cancer drug rucaparib (Rubraca) for use within the Cancer Drugs Fund (CDF).
-
11 October 2019
UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn.
-
11 October 2019
Boehringer’s nintedanib secures breakthrough status in US for ILDs
Boehringer Ingelheim has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for nintedanib in chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
-
11 October 2019
Reata regains rights to bardoxolone from AbbVie for $330m
Reata Pharmaceuticals has reacquired from AbbVie the rights to develop, manufacture and commercialise its Nrf2 activator product bardoxolone methyl in markets outside the US.
-
11 October 2019
Alexion and Stealth to develop elamipretide for mitochondrial diseases
Biopharmaceutical company Alexion Pharmaceuticals has entered a deal with biotechnology firm Stealth BioTherapeutics to develop and commercialise elamipretide to treat mitochondrial diseases.
Close
Close
Close
Go Top
